Skip to Main Content

1,776

Views

2

CrossRef citations to date

0

Altmetric

Letters to Editor

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Paul M. Barra Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USACorrespondence[email protected]

https://orcid.org/0000-0002-9733-401X View further author information

,

Stephen D. Smithb University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information

,

Mark J. Roschewskic National Cancer Institute, Bethesda, MD, USA

https://orcid.org/0000-0003-0278-2635 View further author information

,

Susan M. O’Briend Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USAView further author information

,

Jeff P. Sharmane Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USAView further author information

,

Jason M. Melearf Texas Oncology, Austin, TX, USAView further author information

,

Priti Patelg AstraZeneca, South San Francisco, CA, USAView further author information

,

Roser Calvoh AstraZeneca, Gaithersburg, MD, USAView further author information

,

Helen Yangg AstraZeneca, South San Francisco, CA, USAView further author information

&

Stephen E. Spurgeoni Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USAView further author information